KMDA Kamada Ltd.

Kamada (NASDAQ:KMDA) outlined its growth strategy, product portfolio and financial outlook during a company presentation, emphasizing demand for specialty plasma-derived therapies and a plan to expand through product sales, distribution agreements, plasma supply and potential acquisitions. The comp

KEDRAB sales and distribution expansion drive record revenue and EBITDA growth.

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

KMDA vs. PRTA: Which Stock Is the Better Value Option?

The consensus price target hints at a 79.1% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Kamada Ltd (KMDA) reports its strongest quarter ever with $54.9 million in revenue, a 23% year-over-year increase, while reiterating its full-year guidance.

Moby summary of Kamada Ltd.'s Q2 2026 earnings call

Kamada (NASDAQ:KMDA) reported record revenue and adjusted EBITDA for the second quarter and first half of 2026, driven by higher sales of its specialty plasma-derived products, including KEDRAB, VARIZIG and HEPAGAM. The company reiterated its full-year guidance and said it expects initial sales unde

Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Kamada (KMDA) delivered earnings and revenue surprises of +33.33% and +6.39%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?